- Home
- LPLA vs INM Comparison
LPLA vs INM Comparison
Compare LPLA & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPLA
- INM
- Stock Information
- Founded
- LPLA 1989
- INM 1981
- Country
- LPLA United States
- INM Canada
- Employees
- LPLA N/A
- INM N/A
- Industry
- LPLA Investment Bankers/Brokers/Service
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- LPLA Finance
- INM Health Care
- Exchange
- LPLA Nasdaq
- INM Nasdaq
- Market Cap
- LPLA 26.9B
- INM 4.3M
- IPO Year
- LPLA 2010
- INM N/A
- Fundamental
- Price
- LPLA $336.19
- INM $2.36
- Analyst Decision
- LPLA Buy
- INM
- Analyst Count
- LPLA 13
- INM 0
- Target Price
- LPLA $407.46
- INM N/A
- AVG Volume (30 Days)
- LPLA 856.6K
- INM 47.0K
- Earning Date
- LPLA 10-29-2025
- INM 11-13-2025
- Dividend Yield
- LPLA 0.36%
- INM N/A
- EPS Growth
- LPLA 14.09
- INM N/A
- EPS
- LPLA 14.60
- INM N/A
- Revenue
- LPLA $13,758,121,000.00
- INM $4,920,990.00
- Revenue This Year
- LPLA $33.13
- INM N/A
- Revenue Next Year
- LPLA $17.04
- INM N/A
- P/E Ratio
- LPLA $23.05
- INM N/A
- Revenue Growth
- LPLA 28.54
- INM N/A
- 52 Week Low
- LPLA $208.47
- INM $1.72
- 52 Week High
- LPLA $403.58
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- LPLA 37.07
- INM 56.86
- Support Level
- LPLA $335.94
- INM $2.11
- Resistance Level
- LPLA $352.39
- INM $2.28
- Average True Range (ATR)
- LPLA 9.86
- INM 0.11
- MACD
- LPLA -1.13
- INM 0.03
- Stochastic Oscillator
- LPLA 18.07
- INM 78.57
About LPLA LPL Financial Holdings Inc.
LPL Financial is the largest US independent broker-dealer, with nearly 29,000 financial advisors affiliated with its platform and roughly 10 million associated customer accounts at the end of 2024. The firm earns the bulk of its profit from interest income earned on client cash balances and from advisory fees and commissions tied to the $1.7 trillion in assets under management or advisory on its platform at year-end 2024. LPL specializes in the provision of turnkey wealth management services for affiliated independent advisors, but maintains a diverse array of affiliation modalities, running the gamut from more traditional employee models to a pure RIA custody approach. It earns tuck-in revenue from recordkeeping fees and the provision of software tools and services to its advisor base.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.